DexCom, Inc. (NASDAQ:DXCM) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of DexCom, Inc. (NASDAQ:DXCM) have earned a consensus rating of “Moderate Buy” from the eighteen research firms that are covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $98.00.

DXCM has been the topic of a number of analyst reports. Wells Fargo & Company boosted their target price on shares of DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Raymond James dropped their price objective on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a report on Friday, October 25th. Stifel Nicolaus raised their target price on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, August 23rd. JPMorgan Chase & Co. upped their price target on DexCom from $75.00 to $85.00 and gave the company a “neutral” rating in a research report on Friday, October 25th. Finally, Sanford C. Bernstein raised their price objective on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research report on Friday, October 25th.

Insider Activity

In other DexCom news, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total value of $318,275.07. Following the completion of the sale, the executive vice president now owns 71,192 shares of the company’s stock, valued at $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.30% of the company’s stock.

Institutional Investors Weigh In On DexCom

Hedge funds have recently made changes to their positions in the business. Migdal Insurance & Financial Holdings Ltd. purchased a new position in DexCom in the 2nd quarter worth $25,000. Sachetta LLC grew its stake in shares of DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after buying an additional 171 shares during the last quarter. Riverview Trust Co increased its holdings in shares of DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after buying an additional 232 shares during the period. DT Investment Partners LLC lifted its stake in shares of DexCom by 492.2% in the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after acquiring an additional 315 shares during the last quarter. Finally, RPg Family Wealth Advisory LLC purchased a new stake in DexCom during the 3rd quarter valued at about $57,000. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Performance

NASDAQ DXCM opened at $75.26 on Friday. The firm has a market cap of $29.40 billion, a P/E ratio of 45.07, a price-to-earnings-growth ratio of 2.46 and a beta of 1.12. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The company’s 50 day moving average is $74.19 and its 200-day moving average is $83.40. DexCom has a 12-month low of $62.34 and a 12-month high of $142.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.